Skip to main content
SP5007,711.76-0.25%DOW53,559.99-0.02%NASDAQ26,402.42-0.52%BTC$77,728.00-3.40%ETH$2,441.16-2.91%GOLD$4,504.10-3.43%OIL$83.44-0.11%
Smart Investors Daily
Sign InSign Up Free
HO

OTC · HOOK

HOOKIPA Pharma Inc.

Healthcare · Biotechnology

$1.15

Up+$0.00 (+0.00%)

Updated Aug 29, 2026, 7:49 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
11.02M
P/E ratio
-0.15
Dividend yield
0.00%
52-week range
— – —
Volume
0
Avg. volume
27.52K

Price performance

HOOK price history

1M range · 0 trading sessions · Daily adjusted prices

HOOK does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest HOOK news

The latest Smart Investors Daily articles mentioning HOOK.

Stock researchCompany · Overview

HOOK research

Overview

Company profile and research snapshot.

Company profile

HOOKIPA PHARMA INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$3.00
Implied upside
—
Analysts
6
HOOK recent ratings
DateFirmRatingTarget
Jan 10, 2025HC Wainwright & Co.Neutral—
Dec 20, 2024RBC CapitalSector Perform—
Nov 21, 2024JMP SecuritiesMarket Outperform—
Nov 15, 2024RBC CapitalOutperform—
Aug 9, 2024JMP SecuritiesMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Mar 26, 2026

HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics

Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail TherapeuticsNEW YORK and VIENNA, March 26, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”, the “Company”) today announced the completion of the sale of its immuno-oncology related assets, consisting primarily of the HB-200 (eseba-vec) and HB-700 development programs, to NeoTrail Therapeutics, Inc. (“NeoTrail”). The purchase price remains undisclosed. The asset purcha

globenewswire.com · Oct 31, 2025

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead

NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and certain of its assets related to HOOKIPA's HB-500 program to Gilead Sciences, Inc. (“Gilead”).

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By